TuHURA Biosciences (HURA) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Retension Pharmaceuticals is the larger company by market cap ($117.2 million vs $112.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | RTSN |
|---|---|---|
| Share price | $1.76 | $14.07 |
| Market cap | $112.16M | $117.23M |
| 1-day change | -3.83% | +15.23% |
| YTD return | +132.50% | — |
| 1-year return | -26.67% | — |
| 5-year return | -99.89% | — |
| EPS (TTM) | $-0.54 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-30.05M | — |
| 52-week high | $3.43 | $14.97 |
| 52-week low | $0.41 | $9.66 |
| Distance from 52-week high | -48.69% | -6.02% |
| Analyst consensus | none | — |
| Avg. price target upside | +356.82% | — |
| Average volume | 221.74K | 252.97K |
| Shares outstanding | 63.73M | 8.33M |
| Employees | 22 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
HURA vs RTSN FAQ
Which is bigger, TuHURA Biosciences or Retension Pharmaceuticals?
Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $117.23M compared with $112.16M for TuHURA Biosciences (HURA).
Are TuHURA Biosciences and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.